News & Updates

Show Multimedia Only

Branebrutinib makes no difference in RA management

07 May 2026

A phase 2a trial of rheumatoid arthritis (RA) has shown no significant difference between the investigational branebrutinib and placebo in terms of clinical efficacy, despite the drug having a favourable safety profile.

Branebrutinib makes no difference in RA management

07 May 2026

IPF tied to lower survival than SARD-ILD

29 Apr 2026

Patients with systemic autoimmune rheumatic disease (SARD)-associated interstitial lung disease (ILD) tend to live longer than those with idiopathic pulmonary fibrosis (IPF), reveals a study.

IPF tied to lower survival than SARD-ILD

29 Apr 2026

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

IL-23 inhibitors work best at preventing PsA development in psoriasis

17 Apr 2026 by

Patients with psoriasis appear to have the lowest risk of developing psoriatic arthritis (PsA) when they are treated with IL-23 inhibitors than with other immunomodulatory agents, according to a real-world study.

IL-23 inhibitors work best at preventing PsA development in psoriasis

17 Apr 2026

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

15 Apr 2026

In individuals at risk of rheumatoid arthritis (RA), 12 months of treatment with hydroxychloroquine falls short of preventing the development of the disease, according to the results of a phase II trial.

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

15 Apr 2026

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

14 Apr 2026

Nintedanib is the only antifibrotic approved in Hong Kong for progressive pulmonary fibrosis and systemic sclerosis–associated interstitial lung disease (ILD). Read further on how nintedanib slows lung function decline in connective tissue disease–associated ILD (CTD-ILD), as well as ERS/EULAR 2025 guideline recommendations on screening, diagnosis, monitoring, and treatment of CTD-ILD.

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

14 Apr 2026

ACS patients with SLE require greater healthcare use

13 Apr 2026

Systemic lupus erythematosus (SLE) patients with acute coronary syndrome (ACS) need a longer hospital stay and accrue higher charges, resulting in higher healthcare utilization, reports a study.

ACS patients with SLE require greater healthcare use

13 Apr 2026

Early onset, recurrent illness tied to DADA2 disease damage

13 Apr 2026

In patients with deficiency of adenosine deaminase 2 (DADA2) vasculitis, early age of onset and periodic illness are associated with disease-related damage, but prompt initiation of a tumour necrosis factor inhibitor (TNFi) may prevent complications and severe progression, suggests a study.

Early onset, recurrent illness tied to DADA2 disease damage

13 Apr 2026

LEVI-04 improves knee osteoarthritis outcomes

13 Apr 2026

Treatment with LEVI-04—a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3—helps improve pain and function in patients with knee osteoarthritis, as shown in a phase II trial.

LEVI-04 improves knee osteoarthritis outcomes

13 Apr 2026

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

11 Apr 2026 by

Genetic markers, both in and outside the immune system, influence an individual’s response to the SARS-CoV-2 vaccine, and these effects are similar in patients with or without systemic autoimmune diseases (SADs), reports a study.

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

11 Apr 2026

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Branebrutinib makes no difference in RA management

Branebrutinib makes no difference in RA management

IPF tied to lower survival than SARD-ILD

IPF tied to lower survival than SARD-ILD

Original New Drug Application Approvals by US FDA (16-31 March 2026)

Original New Drug Application Approvals by US FDA (16-31 March 2026)

IL-23 inhibitors work best at preventing PsA development in psoriasis

IL-23 inhibitors work best at preventing PsA development in psoriasis

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

ACS patients with SLE require greater healthcare use

ACS patients with SLE require greater healthcare use

Early onset, recurrent illness tied to DADA2 disease damage

Early onset, recurrent illness tied to DADA2 disease damage

LEVI-04 improves knee osteoarthritis outcomes

LEVI-04 improves knee osteoarthritis outcomes

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients